Bifunctional CDK2/5 Degraders for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CDK inhibitors exhibit significant off-target toxicity due to their broad-spectrum activity, making them ineffective for targeted cancer therapy and other CDK2/5-mediated diseases.
Innovation Solution
Development of bifunctional compounds that selectively degrade CDK2 and CDK5 by conjugating low nanomole potency pan-CDK ligands with an E3 ligase binder, promoting dual degradation while sparing other CDK isoforms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad-spectrum CDK inhibitors are used to target multiple CDK isoforms, then coverage of CDK family members is improved, but off-target toxicity increases
Solution Approach 1:
The patent segments the CDK inhibition function by developing selective inhibitors for specific CDK isoforms (CDK2 and CDK5) rather than using broad-spectrum inhibitors. This is achieved through structurally distinct compounds that target specific CDK active sites, thereby maintaining versatility in treating different CDK-mediated diseases while reducing off-target toxicity by avoiding non-specific CDK family coverage
Solution Approach 2:
The patent applies local quality by designing inhibitors with specific molecular structures tailored to bind only to particular CDK isoforms (CDK2 or CDK5) rather than all CDK members. The inhibitors exhibit selective binding characteristics that provide high affinity for the target CDK while showing minimal activity against other CDK isoforms, thus reducing off-target effects
2Adaptability or versatility
If pan-CDK inhibitors are used to treat various CDK-mediated diseases, then treatment coverage is improved, but therapeutic window narrows due to CDK1 toxicity
Solution Approach 1:
The patent segments the therapeutic approach by developing CDK2 and CDK5 selective inhibitors that can be used to treat diseases mediated by these specific isoforms without the toxicity burden of pan-CDK inhibitors. This segmentation allows for a wider therapeutic window by avoiding CDK1 inhibition while maintaining effectiveness against CDK2/5-mediated pathologies
Solution Approach 2:
The patent extracts the CDK inhibition function from the broader CDK family and applies it selectively to CDK2 and CDK5. By taking out the inhibition activity and directing it only at specific isoforms rather than all CDK members, the therapeutic window is widened by eliminating CDK1-related toxicities while preserving disease-relevant CDK2/5 inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds achieve high target selectivity, reducing off-target effects and providing effective treatments for CDK2/5-mediated diseases such as cancer by promoting the selective degradation of CDK2 and CDK5.
Implementation Method 1
bifunctional compounds that selectively degrade CDK2 and CDK5 by conjugating low nanomole potency pan-CDK ligands with an E3 ligase binder, promoting dual degradation
Data Source
AI summary
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by dysfunctional cyclin-dependent kinase 2 (CDK2) and CDK5 activity.